drugset / Trial / NCT05755854
Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open single-arm clinical study aimed at evaluating the safety and tolerance of allogeneic γ9δ2 T cell injection in the treatment of patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation.
Timeline
- Start
- 2023-05-03
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | allogeneic γ9δ2 T Cells | Cell therapy | 5e+07 cells/kg | — |
| Subject | allogeneic γ9δ2 T Cells | Cell therapy | 1e+08 cells/kg | — |
| Subject | allogeneic γ9δ2 T Cells | Cell therapy | 2e+08 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Zoredronic acid | Unknown | 50 ug/kg | Intravenous |